儿童噬血细胞性淋巴组织细胞增生症的干细胞移植:HLH-2004研究结果
HLH-2004国际研究纳入187例18岁以下符合标准的患儿,共接受209次造血干细胞移植(2004-2012年)。移植后5年总生存率为66%(95%CI 59-72),无事件生存率为60%(95%CI 52-67)。完全缓解者5年总生存率81%,部分缓解者59%(HR 2.12,95%CI 1.06-4.27,P=0.035)。
要点
- 移植后5年总生存率66%,无事件生存率60%。
- 移植前完全缓解者5年总生存率81%,部分缓解者59%。
- 确诊家族性HLH者5年总生存率71%,未确诊者52%。
核心结论
- 家族性HLH移植后生存仍不理想,移植前应仔细排查家族性HLH诊断。
- 移植前完全缓解有益,但并非移植后生存的必要条件。
研究设计与样本
- 国际HLH-2004前瞻性研究,纳入187例18岁以下符合入选标准的患儿,共接受209次造血干细胞移植(2004-2012年)。
主要发现
- 移植后5年总生存率为66%(95%CI 59-72),无事件生存率为60%(95%CI 52-67)。
- 完全缓解患儿5年总生存率为81%(95%CI 65-90),部分缓解患儿为59%(95%CI 48-69)(HR 2.12;95%CI 1.06-4.27;P=0.035)。
- 确诊家族性HLH患儿(n=134)5年总生存率为71%(95%CI 62-78),无事件生存率为62%(95%CI 54-70)。
- 未确诊家族性HLH患儿(n=53)5年总生存率为52%(95%CI 38-65),显著低于确诊组(P=0.040;HR 1.69;95%CI 1.03-2.77),且年龄显著更大。
- 未确诊家族性HLH的53例中,20例(38%)在诊断时、2个月后或移植时报告自然杀伤细胞活性正常,提示继发性HLH;14例(26%)在分析3或4个家族性HLH基因后未见双等位基因突变证据(2个月后或移植时未分析自然杀伤细胞活性)。
临床怎么用
- 作者认为移植前应仔细排查家族性HLH诊断。
- 作者认为移植前完全缓解有益,但并非移植后生存的必要条件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We report the largest prospective study thus far on hematopoietic stem cell transplantation (HSCT) in hemophagocytic lymphohistiocytosis (HLH), a life-threatening hyperinflammatory syndrome comprising familial/genetic HLH (FHL) and secondary HLH. Although all patients with HLH typically need intensive anti-inflammatory therapy, patients with FHL also need HSCT to be cured. In the international HLH-2004 study, 187 children aged <18 years fulfilling the study inclusion criteria (5 of 8 diagnostic criteria, affected sibling, or molecular diagnosis in FHL-causative genes) underwent 209 transplants (2004-2012), defined as indicated in patients with familial/genetic, relapsing, or severe/persistent disease. Five-year overall survival (OS) post-HSCT was 66% (95% confidence interval [CI], 59-72); event-free survival (EFS) was 60% (95% CI, 52-67). Five-year OS was 81% (95% CI, 65-90) for children with a complete response and 59% (95% CI, 48-69) for those with a partial response (hazard ratio [HR], 2.12; 95% CI, 1.06-4.27; P = .035). For children with verified FHL (family history/genetically verified, n = 134), 5-year OS was 71% (95% CI, 62-78) and EFS was 62% (95% CI, 54-70); 5-year OS for children without verified FHL (n = 53) was significantly lower (52%; 95% CI, 38-65) (P = .040; HR, 1.69; 95% CI, 1.03-2.77); they were also significantly older. Notably, 20 (38%) of 53 patients without verified FHL had natural killer cell activity reported as normal at diagnosis, after 2 months, or at HSCT, suggestive of secondary HLH; and in addition 14 (26%) of these 53 children had no evidence of biallelic mutations despite having 3 or 4 FHL genes analyzed (natural killer cell activity not analyzed after 2 months or at HSCT). We conclude that post-HSCT survival in FHL remains suboptimal, and that the FHL diagnosis should be carefully investigated before HSCT. Pretransplant complete remission is beneficial but not mandatory to achieve post-HSCT survival. This trial was registered at www.clinicaltrials.gov as #NCT00426101.
引用
- Bergsten E, Horne A, Hed Myrberg I, et al. Stem cell transplantation for children with hemophagocytic lymphohistiocytosis: results from the HLH-2004 study. Blood Adv. 2020. PMID: 32780845. doi:10.1182/bloodadvances.2020002101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。